Cyclerion Therapeutics In... (CYCN)
Cyclerion Therapeutics Statistics
Share Statistics
Cyclerion Therapeutics has 2.71M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 2.71M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.02% |
| Shares Floating | 1.83M |
| Failed to Deliver (FTD) Shares | 115 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 14.44K, so 0.53% of the outstanding shares have been sold short.
| Short Interest | 14.44K |
| Short % of Shares Out | 0.53% |
| Short % of Float | 0.74% |
| Short Ratio (days to cover) | 0.78 |
Valuation Ratios
The PE ratio is -0.37 and the forward PE ratio is -1.87. Cyclerion Therapeutics's PEG ratio is 0.01.
| PE Ratio | -0.37 |
| Forward PE | -1.87 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0.69 |
| P/FCF Ratio | -0.37 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cyclerion Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.85, with a Debt / Equity ratio of 0.
| Current Ratio | 3.85 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.86% and return on capital (ROIC) is -85.46%.
| Return on Equity (ROE) | -1.86% |
| Return on Assets (ROA) | -1.57% |
| Return on Capital (ROIC) | -85.46% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-21,015,000 |
| Employee Count | 1 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -25% in the last 52 weeks. The beta is 2.09, so Cyclerion Therapeutics's price volatility has been higher than the market average.
| Beta | 2.09 |
| 52-Week Price Change | -25% |
| 50-Day Moving Average | 3.17 |
| 200-Day Moving Average | 2.89 |
| Relative Strength Index (RSI) | 38.93 |
| Average Volume (20 Days) | 4.62M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -9.65M |
| Net Income | -21.02M |
| EBITDA | -12.59M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -8.99 |
Balance Sheet
The company has 7.57M in cash and 0 in debt, giving a net cash position of 7.57M.
| Cash & Cash Equivalents | 7.57M |
| Total Debt | 0 |
| Net Cash | 7.57M |
| Retained Earnings | -264.42M |
| Total Assets | 8.9M |
| Working Capital | 2.85M |
Cash Flow
In the last 12 months, operating cash flow was -21.25M and capital expenditures 0, giving a free cash flow of -21.25M.
| Operating Cash Flow | -21.25M |
| Capital Expenditures | 0 |
| Free Cash Flow | -21.25M |
| FCF Per Share | -9.09 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYCN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -374.58% |
| FCF Yield | -326.63% |
Analyst Forecast
Currently there are no analyst rating for CYCN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 16, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | May 16, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -37.68 |
| Piotroski F-Score | 2 |